Pharmacological treatment of priority mental, neurological and substance use disorders in non-specialized health care: a job aid for supporting implementation of the mhGAP guidelines

Pharmacological treatment of priority mental, neurological and substance use disorders in non-specialized health care: a job aid for supporting implementation of the mhGAP guidelines

9789292742324-engMental, neurological and substance use (MNS) disorders are common in all regions of the world, affecting every community and age group across all countries, regardless of income. Some 10% of the global burden of disease is attributed to these disorders, but the World Health Organization (WHO) estimates that only 29% of people with psychosis and 40% of people with depression receive mental health services. The gaps in treatment vary across countries and from one mental health condition to another. For example, while 70% of people with psychosis are reported to be treated in high-income countries, only 12% receive mental health care in low-income countries. For depression, the gaps in service coverage are wide across all countries: even in high-income countries, nearly half of people with moderate to severe depression do not receive formal mental health care.